Canada doubles the order for Moderna’s experimental COVID-19 vaccine

By: Miguel A. Rodriguez

17:56, 07 December 2020

Moderna’s stock gains as orders doubles

The race for releasing a viable COVID-19 vaccine intensified in the past couple of weeks. After Pfizer and BioNTech, Moderna also filed for approval in the UK and the US, countries increase their dose orders.

According to Moderna, the Canadian government doubled its order for its COVID-19 vaccine candidate. If the country initially ordered 20 million doses, it has now exercised its option to order 20 million more doses. Overall, the government will benefit from 40 million doses. The doses will come from Moderna’s site in Europe.

Despite the increase, Moderna stated that it is on track with its start date of shipping mRNA-1273 later on this month, if approved by regulators.

Following the news, the company’s stock price traded 1.3% higher. In the last quarter, Moderna stock price is up more than 146%, while USA500 added 7.8%.


Share this article

This information prepared by is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation, or the particular needs of any recipient.You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation, or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.This information may not be published, circulated, reproduced, or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of Financial Services (Pty) Ltd trading as CAPEX.COM/ZA acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via CAPEX.COM/ZA, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15.  Magnasale Trading Ltd is the principal to the CFD purchased by investors.